Mattias C V Carlsten

Title: Mattias C V Carlsten: Innovator in Cancer Treatment

Introduction

Mattias C V Carlsten is a prominent inventor based in Bethesda, MD (US). He has made significant contributions to the field of cancer treatment through his innovative research and patented technologies. His work focuses on enhancing the efficacy of natural killer (NK) cells in targeting tumors.

Latest Patents

Carlsten holds a patent for "NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors." This patent discloses modified NK cells, compositions comprising these modified NK cells, and methods for treating tumors or hyperproliferative diseases in subjects. The modified NK cells include a heterologous nucleic acid molecule encoding a CD16 protein with a valine at amino acid position 158 (CD16-V158) and a heterologous nucleic acid molecule encoding a CCR7 protein. The methods described involve treating subjects with tumors by administering a composition that includes an anti-cancer monoclonal antibody alongside the modified NK cells.

Career Highlights

Carlsten's career is marked by his dedication to advancing cancer therapies. He works for the United States of America, as Represented by the Secretary, Department of Health and Human Services. His innovative approaches have garnered attention in the scientific community, particularly for their potential to improve cancer treatment outcomes.

Collaborations

One of his notable collaborators is Richard W Childs, with whom he has worked on various projects related to NK cell modifications and cancer therapies.

Conclusion

Mattias C V Carlsten is a key figure in the development of advanced cancer treatments through his innovative work with NK cells. His contributions are paving the way for more effective therapies in the fight against cancer.